Competition in the generics market is becoming increasingly intense. There is still room for growth in the more mature generics markets, with governments examining methods of increasing generic usage even further. Low competition & higher profitability seem to be the critical drivers for innovative generics.
Top line growth of the pharma business beyond 2016 is estimated nearly $1.4 trillion in drug sales by 2020. Two-thirds of the growth between 2012 and 2020 is forecasted to come from emerging countries, including BRICS. Approximately 50% of future global drug market growth will come from generics. And estimations are that the super generics can generate 7 to 10 times value of plain generics with all the top global generic players including the Indian companies having a ‘super-generic’ strategy in place and making investments accordingly.
We bring you Innogen Summit India 2016 designed to keep you up to date with the latest legislative, regulatory, and global developments in the generic marketplace, whilst providing networking opportunities with the key industry decision makers.